EE785 Impact of Choices in Cost-Effectiveness Analysis of Recombinant Zoster Vaccine Among 65 Years Old and Older in France

Abstract

Authors

P Loubet B Tehard A Grangeon ML Nishimwe P Jacquemet L Roustand L Di Meglio G Nachbaur G De Pouvourville